NGM 1.54 (+0%)
US62921N1054BiotechnologyBiotechnology

NGM Biopharmaceuticals (NGM) Stock Highlights

1.54 | +0%
2024-12-21 06:41:55
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The companys products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.

Statistics

Range Today
1.54 1.54
Volume Today 0
Range 1 Year
0.6 4.69
Volume 1 Year 163.5M
Range 3 Year
0.6 30.13
Volume 3 Year 385.53M
Range 10 Year
0.6 32.12
Volume 10 Year 502.09M

Highlights

Market Capitalization 128.53M (small)
Floating Shares 28.89M
Current Price 1.54
Price To Earnings 0
Price To Revenue -2.03
Price To Book 0.86
Earnings Per Share -1.73
Payout Ratio 0%

Performance

Latest 0%
1 Month +0.65%
3 Months +13.24%
6 Months +21.26%
1 Year -59.79%
3 Years -94.22%
5 Years -89.88%
10 Years -89.73%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.